Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 February 2006

Bifenthrin inhibits neurite outgrowth in differentiating PC12 cells.

Van Tran, Natalie Hoffman, Adaobi Mofunanaya, Stephen Pryor, Olutosin Ojugbele, Ashlea McLaughlin, Lydia Gibson, Josephine A. Bonventre, Katherine Flynn, Benjamin Weeks

Med Sci Monit 2006; 12(2): BR57-62 :: ID: 445228

Abstract

Background: Bifenthrin is a third generation member of the synthetic pyrethroidfamily of insecticides. As a new pesticide within a relatively new class of pesticides, bifenthrin isconsidered relatively safe. Here, we used the PC12 neuronal cell line to examine the effect of bifenthrinon the formation of neurites and the potential developmental neurotoxicity of this pesticide. Material/Methods:PC12 cells were exposed to varying concentrations of technical grade bifenthrin or Ortho Home Defense[sup]®[/sup].Cell viability was determined using the AlmarBlue Toxicity Assay. Nontoxic concentrations of these chemicalswere concomitantly with nerve growth factor and neurite outgrowth was assessed. Results: Ortho Home Defense[sup]®[/sup]preparation reduced PC12 cell viability by approximately 50% and 70% at dilutions that correlate to bifenthrinconcentrations of 10[sup]-5[/sup] M and 10[sup]®[/sup] M, respectively. In contrast, technical grade bifenthrin, was nottoxic to PC12 cells at 10[sup]-3[/sup] M, which was the highest concentration tested that was soluble. At "nontoxic"concentrations of 10[sup]-7[/sup] M and 10[sup]-6[/sup] M, the Ortho Home Defense[sup]®[/sup] inhibited nerve growth factor-mediatedneurite outgrowth by 30% and 55% respectively. Furthermore the nontoxic concentrations of technical gradebifenthrin of 10[sup]-6[/sup] M and 10[sup]-3[/sup] M inhibited neurite outgrowth by approximately 35% and 75% respectively.Conclusions: These data suggest that the toxicity of the Ortho Home Defense[sup]®[/sup] preparation was dueto the "inert" additives in the preparation and not the bifenthrin itself. Further, these data suggestthat, even in the absence of overt toxicity, bifenthrin may have deleterious effects to developing nervoussystem.

Keywords: Cell Survival - drug effects, Insecticides - toxicity, Neurites - pathology, Neurotoxins - toxicity, Pyrethrins - toxicity

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

26 Feb 2024 : Clinical Research  

Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...

Med Sci Monit In Press; DOI: 10.12659/MSM.942509  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750